Skip to main content
. Author manuscript; available in PMC: 2020 Sep 30.
Published in final edited form as: Am J Obstet Gynecol. 2018 Dec 21;220(4):381.e1–381.e14. doi: 10.1016/j.ajog.2018.12.030

TABLE 1.

Patient demographics (N = 768)

Features set 1 (20 features) Measure Features set 2,a n (%) Measure Features set 3,b n (%) Measure
Age, yc 49 (41–58) Histologic condition Beta-blocker use
Race/ethnicity, n (%)  Squamous cell 578 (75.3)  No 710 (92.9)
 White 64 (8.3)  Adenocarcinoma 137 (17.8)  Yes 54 (7.1)
 Black 48 (6.3)  Adenosquamous 31 (4.0) Primary hysterectomy
 Hispanic 551 (71.7)  Other 22 (2.9)  No 559 (72.8)
 Asian 101 (13.2) Stage  Yes 209 (27.2)
 Others 4 (0.5)  I 372 (48.7) Radiotherapy
Body mass index, kg/m2c,d 28.0 (24.3–32.8)   IA1 91 (11.8)  No 297 (38.7)
Hypertension, n (%)e   IA2 21 (2.7)  Yes 471 (61.3)
 No 569 (74.5)   IB1 160 (20.8) Chemotherapy
 Yes 195 (25.5)   IB2 100 (13.0)  No 699 (91.0)
Diabetes mellitus, n (%)e  II 167 (21.9)  Yes 69 (9.0)
 No 654 (85.6)   IIA 30 (3.9)
 Yes 110 (14.4)   IIB 136 (17.7)
Hypercholesterolemia, n (%)e   II NOS 1 (0.1)
 No 701 (91.8)  III 156 (20.4)
 Yes 63 (8.2)   IIIA 7 (0.9)
Vital signs at diagnosisc   IIB 149 (19.4)
 Systolic blood pressure, mm Hg 125 (112–140)  IV 69 (9.0)
 Diastolic blood pressure, mm Hg 72 (65–80)   IVA 11 (1.4)
 Heart rate, beats/min 79 (70–89)   IVB 58 (7.6)
Laboratory testc  Unknown 4 (0.5)
 White blood cell, ×109/L 8.3 (6.6–10.0)
 Platelet, ×109/L 300 (244–451)
 Hemoglobin, g/dL 12.3 (10.2–13.4)
 Blood urea nitrogen, mg/dL 12.0 (9.0–15.0)
 Creatinine, mg/dL 0.6 (0.5–0.8)
 Bicarbonate, mEq/L 25 (23–27)
 Albumin, g/dL 4.1 (3.7–4.4)
a

Included the demographics for features set 1 and the 16 listed tumor features

b

Included the demographics for features set 1, the 16 tumor features for features set 2, and the listed treatment features

c

Data are given as median (interquartile range)

d

Missing 20 data

e

Missing 4 data.